This section provides advanced pharmacogenomic guidance specifically tailored to the CBS/PSP treatment plan, building upon the foundational pharmacogenomics covered in Section 160. While Section 160 covers the core CYP450 system and general drug metabolism, Section 216 focuses on:
The APOE gene (Apolipoprotein E) has three common alleles: ε2, ε3, and ε4[1]. While most commonly studied in Alzheimer's disease, APOE status has implications for CBS/PSP patients:
| APOE Genotype | Protein Function | Clinical Relevance |
|---|---|---|
| ε3/ε3 | Normal function | Reference genotype |
| ε2/ε2 or ε2/ε3 | Reduced Aβ binding | Possible neuroprotective effect |
| ε3/ε4 | Intermediate | Increased Aβ accumulation risk |
| ε4/ε4 | Enhanced Aβ binding | Highest AD risk, may affect cognition |
Cognitive Therapies:
Statin Therapy:
Anti-inflammatory Therapies:
When to Test APOE:
Testing Services:
Both rasagiline and selegiline are MAO-B inhibitors used in Parkinsonism[2]. Their metabolism involves:
CYP1A2 Polymorphisms:
Clinical Implications:
| CYP1A2 Status | Selegiline Dosing | Clinical Consideration |
|---|---|---|
| Normal Metabolizer | Standard doses | Monitor response |
| Induced (1F carrier) | May need higher doses | Consider therapeutic monitoring |
| Inhibited | Consider dose reduction | Avoid combining with strong inhibitors |
While Section 160 covers COMT polymorphisms, this section addresses additional genetic factors[3]:
SLC22A1 (OCT1) Variants:
SLC6A3 (DAT1) Polymorphisms:
| Gene | Polymorphism | Drug Class | Effect | Action |
|---|---|---|---|---|
| COMT | Val158Met | Levodopa | Val/Val: faster metabolism | Consider COMT inhibitor |
| SLC22A1 | Various | Levodopa | Reduced function: altered transport | Monitor response |
| DRD2 | Taq1A | Dopamine agonists | Altered receptor density | May affect efficacy |
| DRD3 | Ser9Gly | Dopamine agonists | May influence dyskinesia risk | Monitor |
The SLC6A2 gene encodes the norepinephrine transporter, critical for reuptake of norepinephrine and dopamine[4]. NET polymorphisms affect:
NET Variants (SLC6A2):
For CBS/PSP Patients:
Monitoring:
For CBS/PSP patients on complex medication regimens, consider this integrated approach:
| Gene | Genotype | Drug | Modification |
|---|---|---|---|
| CYP2D6 | PM | Fluoxetine, paroxetine | Avoid or reduce 50% |
| CYP2D6 | UM | Tramadol, codeine | Avoid, use alternative |
| CYP2C19 | PM | Escitalopram | Reduce 50% |
| COMT | Val/Val | Levodopa | Increase frequency |
| COMT | Met/Met | Levodopa | Reduce dose if dyskinesias |
| CYP1A2 | Induced | Selegiline | May need higher dose |
| APOE | ε4/ε4 | Donepezil | Monitor closely |
Step 1: Medication Audit
Step 2: Genetic Testing Selection
Step 3: Results Interpretation
Step 4: Dosing Optimization
| Clinical Scenario | Recommended Testing |
|---|---|
| Poor levodopa response | COMT, SLC22A1, DRD2 |
| Antidepressant failure | CYP2D6, CYP2C19, SLC6A4, NET |
| Unexplained drug toxicity | Full CYP450 panel |
| Cognitive therapy planning | APOE |
| Multiple drug interactions | Comprehensive panel |
This section integrates with the CBS/PSP treatment plan at these points:
For patients with atypical parkinsonism (CBS/PSP) on dopaminergic therapy, understanding CYP2D6 and CYP3A4 status is essential for optimizing treatment. This section specifically addresses the pharmacogenomics of levodopa and rasagiline — two commonly prescribed medications.
Patient Profile for This Section:
While levodopa is primarily metabolized by COMT and DOPAC, CYP2D6 plays a minor but clinically relevant role:
Rasagiline is primarily metabolized by CYP1A2, but CYP2D6 and CYP3A4 also contribute:
| Enzyme | Contribution | Clinical Note |
|---|---|---|
| CYP1A2 | Primary (60-70%) | Major pathway |
| CYP3A4 | Secondary (20-30%) | Significant |
| CYP2D6 | Minor (5-10%) | Less clinically relevant |
| Phenotype | Levodopa | Rasagiline | Recommendation |
|---|---|---|---|
| Poor Metabolizer | Standard dose | May have slightly increased exposure | Monitor for side effects |
| Intermediate Metabolizer | Standard dose | Standard dose | Monitor response |
| Normal Metabolizer | Standard dose | Standard dose | Standard dosing |
| Ultrarapid Metabolizer | Standard dose | May have reduced efficacy | Consider therapeutic monitoring |
Both levodopa and rasagiline have CYP3A4-mediated metabolism:
Rasagiline and CYP3A4:
Levodopa and CYP3A4:
| CYP3A4 Status | Effect on Rasagiline | Clinical Action |
|---|---|---|
| Wild-type (*1) | Normal metabolism | Standard dose |
| *22 (reduced function) | Increased exposure | Consider dose reduction |
| Induced | Reduced exposure | Monitor efficacy |
| Inhibited (drugs/food) | Increased exposure | Avoid or reduce dose |
For the 50-year-old male patient on levodopa and rasagiline:
| Concomitant Drug | CYP Effect | Levodopa | Rasagiline | Action |
|---|---|---|---|---|
| Fluoxetine | Inhibitor (2D6, 2C19) | Monitor | Monitor | Avoid if possible |
| Paroxetine | Strong inhibitor (2D6) | Monitor | Monitor | Avoid if possible |
| Carbamazepine | Inducer (3A4, 2D6) | May reduce effect | May reduce effect | Consider dose increase |
| Rifampin | Strong inducer (3A4) | May reduce effect | May reduce effect | Avoid or increase dose |
| Ketoconazole | Strong inhibitor (3A4) | Monitor | Significant increase | Avoid combination |
| Grapefruit juice | Inhibitor (3A4) | Minimal | Significant increase | Avoid entirely |
Indications:
Indications:
| Gene | Test For | Action Based on Result |
|---|---|---|
| CYP2D6 | *3, *4, *5, *6, *10, *41, copy number | Guide concomitant medication selection |
| CYP3A4 | *22 | Adjust rasagiline if needed |
| COMT | Val158Met | Optimize levodopa dosing |
| CYP1A2 | *1F | Adjust rasagiline (primary enzyme) |
Baseline Assessment:
Monitoring Parameters:
Dose Adjustment Algorithm:
Avoid:
Consider:
| Parameter | Current Status | Recommendation |
|---|---|---|
| Diagnosis | Possible CBS/PSP | Continue diagnostic workup |
| Medications | Levodopa, Rasagiline | Current regimen appropriate |
| CYP2D6 | Unknown | Consider testing if on additional medications |
| CYP3A4 | Unknown | Consider testing |
| COMT | Unknown | Consider testing for levodopa optimization |
| Next Steps | - | Complete pharmacogenomic testing, optimize doses based on results |
APOE genotype and response to dopaminergic therapy in Parkinson's disease (2023). 2023. ↩︎
MAO-B inhibitor pharmacogenomics in Parkinsonism (2021). 2021. ↩︎
Pharmacogenetics of levodopa response in Parkinsonian disorders (2023). 2023. ↩︎
Norepinephrine transporter polymorphisms and antidepressant response (2022). 2022. ↩︎